Regenerex Pharma Reports Delayed Quarterly Filings; 2025 10-K Filed Late

What Happened
Regenerex Pharma, Inc. announced in an 8-K (filed 2026-09-01) that it recently completed and filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 after the applicable deadline. The company also disclosed that its Quarterly Reports on Form 10-Q for the periods ended March 31, 2026 and June 30, 2026 have not yet been filed and are delinquent.

Key Details

• 2025 Form 10-K: Completed and filed after the filing deadline (described as filed recently in the 8-K).
• Outstanding Quarterly Reports: Form 10-Qs for the quarters ended March 31, 2026 and June 30, 2026 remain unfiled/delinquent.
• No 12b-25 filings: The company did not file Form 12b-25 (Notification of Late Filing) for the delinquent quarters.
• Reason given: Delays due to significant additional accounting, reconciliation and review work related to the late 2025 10-K and preparation of quarterly financial statements; management and advisors are actively working to complete and file the missing reports as soon as practicable.

Why It Matters
Timely Form 10-Q filings provide investors with up-to-date quarterly results, so the missing reports mean that Regenerex’s recent quarterly financial information should be considered incomplete until the 10-Qs are filed. The company states it does not expect the delays to change its operations and is taking steps to strengthen financial reporting processes, but investors should monitor future filings for the completed quarterly results and any updates on timing or regulatory consequences.